Metabolism of the HIV-1 reverse transcriptase inhibitor delavirdine in mice

Drug Metabolism and Disposition

Volumn 25, Issue 7, 1997, Pages 828-839

  Chang, Mayland ^a   Sood, Virendra K ^b   Wilson, Gracella J ^b   Kloosterman, David A ^b   Sanders, Phillip E ^b   Hauer, Michael J ^b   Zhang, Weirong ^b   Branstetter, Daniel G ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DELAVIRDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; DRUG DISPOSITION; DRUG EXCRETION; DRUG METABOLISM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-HIV AGENTS; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAVIRDINE; FECES; FEMALE; HIV-1; HYDROLYSIS; INDOLES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MICE; PIPERAZINES; REVERSE TRANSCRIPTASE INHIBITORS; SPECTROPHOTOMETRY, ULTRAVIOLET; TISSUE DISTRIBUTION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030854082     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. J. S. Mann and D. Tarantola: Coming to terms with the AIDS pandemic. Issues in Science (Washington DC) and Technology Spring, 41-48 (1993).
2. Y. N. Vaishnav and F. Wong-Staal: The biochemistry of AIDS. Annu. Rev. Biochem. 60, 577-630 (1991).
3. H. Mitsuya, R. Yarchoan, and S. Broder: Molecular targets for AIDS therapy. Science (Washington D. C.) 249, 1533-1544 (1990).
4. E. De Clercq: Targets and strategies for the antiviral chemotherapy of AIDS. Trends Pharmacol. Sci. 11, 198-205 (1990).
5. M. A. Fischl, D. D. Richman, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, R. T. Schooley, G. G. Jackson, D. T. Durack, D. King, and The AZT Collaborative Working Group: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N. Engl. J. Med. 317, 185-191 (1987).
6. R. Yarchoan, H. Mitsuya, C. E. Myers, and S. Broder: Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N. Engl. J. Med. 321, 726-738 (1989).
7. R. Yarchoan, H. Mitsuya, R. V. Thomas, J. M. Pluda, N. R. Hartman, C.-F. Perno, K. S. Marczyk, J. P. Allain, D. G. Johns, and S. Broder: In vivo activity against HIV and favorable toxicity profile of 2′,3′-dideoxyinosine. Science (Washington, DC) 245, 412-417 (1989).
8. J. S. Lambert, M. Seidlin, R. C. Reichman, C. S. Plank, M. Laverty, G. D. Morse, C. Knupp, C. McLaren, C. Pettinelli, F. T. Valentine, and R. Dolin: 2′,3′-Dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: a phase I trial. N. Engl. J. Med. 322, 1333-1340 (1990).
9. T. P. Cooley, L. M. Kunches, C. A. Saunders, J. K. Ritter, C. J. Perkins, C. McLaren, R. P. McCaffrey, and H. A. Liebman: Once-daily administration of 2′, 3′-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a phase I trial. N. Engl. J. Med. 322, 1340-1345 (1990).
10. R. Yarchoan, R. V. Thomas, J.-P. Allain, N. McAtee, R. Dubinsky, H. Mitsuya, T. J. Lawley, B. Safai, C. E. Myers, C. F. Perno, R. W. Klecker, R. J. Wills, M. A. Fischl, M. C. McNeely, J. M. Pluda, M. Leuther, J. M. Collins, and S. Broder: Phase I studies of 2′-3′dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1, 76-81 (1988).
11. S. A. Riddler, R. E. Anderson, and J. W. Mellors: Antiretroviral activity of stavudine (2′,3′-didehydro-3′-deoxythymidine, d4T). Antiviral Res. 27, 189-203 (1995).
12. H. Soudeyns, X.-J. Yao, Q. Gao, B. Belleau, J.-L. Kraus, N. Nguyen-ba, B. Spira, and M. A. Wainberg: Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocylic nucleoside analog. Antimicrob. Agents Chemother. 35, 1386-1390 (1991).
13. J. A. V. Coates, N. Cammack, H. J. Jenkinson, A. J. Jowett, M. I. Jowett, B. A. Pearson, C. R. Penn, P. L. Rouse, K. C. Viner, and J. M. Cameron. (-)-2′-Deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob. Agents Chemother. 36, 733-739 (1992).
14. D. D. Richman, M. A. Fischl, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, M. S. Hirsch, G. G. Jackson, D. T. Durack, S. Nusinoff-Lehrman., and The AZT Collaborative Working Group: The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: A double-blind, placebo-controlled trial. N. Engl. J. Med. 317, 192-197 (1987).
15. H. König, E. Behr, J. Löwer, and R. Kurth: Azidothymidine triphosphate is an inhibitor of both human immunodeficiency virus type I reverse transcriptase and DNA polymerase gamma. Antimicrob. Agents Chemother. 33, 2109-2114 (1989).
16. B. A. Larder and S. D. Kemp: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science (Washington, DC) 246, 1155-1158 (1989).
17. B. A. Larder, G. Darby, and D. D. Richman: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science (Washington, DC) 243, 1731-1734 (1989).
18. P. Kellam, C. A. B. Boucher, and B. A. Larder: Fifth mutation in a human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 89, 1934-1938 (1992).
19. M. H. St. Clair, J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder: Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science (Washington, DC) 253, 1557-1559 (1991).
20. R. Schuurman, M. Nijhuis, R. van Leeuwen, P. Schipper, D. de Jong, P. Collis, S. A. Danner, J. Mulder, C. Loveday, C. Christopherson, S. Kwok, J. Sninsky, and C. A. B. Boucher: Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 17, 1411-1419 (1995).
21. T. J. Dueweke, S. M. Poppe, D. L. Romero, S. M. Swaney, A. G. So, K. M. Downey, I. W. Althaus, F. Reusser, M. Busso, L. Resnick, D. Mayers, J. Lane, P. A. Aristoff, R. C. Thomas, and W. G. Tarpley: U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 37, 1127-1131 (1993).
22. D. L. Romero, R. A. Morge, M. J. Genin, C. Biles, M. Busso, L. Resnick, I. W. Althaus, F. Reusser, R. C. Thomas, and W. G. Tarpley. Bis(heteroaryl)piperazine (BHAP): reverse transcriptase inhibitors: Structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3-[(1-methylethyl)amino]- pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate. J. Med. Chem. 36, 1505-1508 (1993).
23. A. Bax, R. H. Griffey, and B. L. Hawkins: Correlation of proton and nitrogen-15 chemical shifts by multiple quantum NMR. J. Magn. Reson. 55, 301-315 (1983).
24. A. Bax and M. F. Summers: Proton and carbon-13 assignments from sensitivity-enhanced detection of heteronuclear multiple-bond connectivity by 2D multiple quantum NMR. J. Am. Chem. Soc. 108, 2093-2094 (1986).
25. A. J. Shaka, P. B. Barker, and R. Freeman: Computer-optimized decoupling scheme for wideband applications and low-level operation. J. Magn. Reson. 64, 547-552 (1985).
26. D. M. Doddrell, D. T. Pegg, and M. R. Bendall: Distortionless enhancement of NMR signals by polarization transfer. J. Magn. Reson. 64, 547-552 (1985).
27. M. Chang, V. K. Sood, G. J. Wilson, D. A. Kloosterman, P. E. Sanders, M. J. Hauer, and P. E. Fagerness: Metabolism of the reverse transcriptase inhibitor delavirdine in rats. Drug Metab. Dispos. 25, 228-242 (1997).
28. V. K. Sood, D. A. Kloosterman, P. E. Sanders, M. J. Hauer, J. J. Vrbanac, and M. Chang: Metabolism of the reverse transcriptase inhibitor delavirdine: Identification of novel N-acetylglucosamine and pyridinol sulfate conjugates. Presented at "Fourth International Meeting of the International Society for the Study of Xenobiotics," (Abstract), Seattle, 1995.
29. V. K. Sood, W. Zhang, D. G. Branstetter, and M. Chang. Mechanism of delavirdine-induced pseudopregnancy in mice. Presented at "Seventh North American Meeting of the International Society for the Study of Xenobiotics," (Abstract), San Diego, 1996.